Hikma Pharmaceuticals is set to acquire the US finished dosage form business of Xellia Pharmaceuticals to enhance its manufacturing capabilities and product portfolio in the injectable medicine market.

Information on the Target

Xellia Pharmaceuticals is a prominent player in the pharmaceutical industry, focusing primarily on developing and manufacturing injectable medicines. Hikma Pharmaceuticals has recently initiated the acquisition of Xellia's US finished dosage form business, encompassing a broad commercial portfolio and a pipeline of innovative products. This deal includes key assets such as a manufacturing facility located in Bedford, Ohio, alongside solid sales and marketing capabilities and a research and development center based in Zagreb, Croatia.

The acquisition allows Hikma to leverage Xellia's existing infrastructure to enhance its production capabilities, particularly in the generic injectable sector, which is witnessing increasing demand. The strategic goal of incorporating Xellia’s US operations is not only to bolster Hikma’s market position but also to expand its offerings in complex manufacturing technologies critical for modern healthcare.

Industry Overview in the Target’s Specific Country

The US pharmaceutical industry is a robust sector, recognized for its advanced research and development capabilities. It consistently leads global pharmaceutical sales, with a significant share attrib